What type of study is this?

September 10, 2025Open Access

Eligibility for icosapent ethyl 1–3 months after acute coronary syndrome and the risk for myocardial re-infarction: Data from the CALLINICUS-Hellas Registry

Key Points

Patients eligible for icosapent ethyl showed a higher risk of non-fatal myocardial reinfarction within 12 months.
Approximately 25.6% of post-ACS patients met the criteria for receiving icosapent ethyl, with diabetes showing a higher eligibility of 32.6%.
The CALLINICUS-Hellas registry assessed 1254 ACS patients, evaluating their lipid profiles and corresponding CV events.
Findings highlight that early Icosapent ethyl administration could help reduce the residual cardiovascular risk associated with high triglycerides.

Abstract

Icosapent ethyl (IPE) has been shown to reduce adverse cardiovascular (CV) outcomes in high or very high-risk patients on statins with triglyceride (TG) levels between 135 and 499 mg/dL METHODS: The CALLINICUS-Hellas registry is an ongoing, prospective, multicenter study evaluating lipid profiles, adherence to lipid-lowering therapies, and prognosis in acute coronary syndrome (ACS) patients. This analysis included patients with lipids assessed 4-12 weeks post-ACS who were divided into two groups: Those eligible for IPE administration according to the 2019 ESC/EAS guidelines for the Management of Dyslipidaemias and those not eligible. Cardiometabolic profile at discharge and the incidence of 3-point major adverse CV events 3P-MACE; non-fatal myocardial infarction (MI), non-fatal stroke, cardiac death within 12 months were compared between groups RESULTS: A total of 1254 patients had their lipid profile evaluated 4-12 weeks post-discharge and the vast majority (97.1 %) were on statins. Of those, 25.6 % were eligible for IPE administration while among patients with diabetes mellitus (DM) the eligibility was higher (32.6 %). IPE-eligibility was associated with an adverse cardiometabolic profile (higher prevalence of DM, hypertension, obesity and atherogenic dyslipidemia) and an increased risk of non-fatal MI within 12 months (5.9 % vs. 3.1 %, p = 0.027), even after adjustment for potential confounders. Rates of 3P-MACE, non-fatal stroke and cardiac death were similar between subgroups CONCLUSION: Approximately 1 in 4 post-ACS patients fulfill IPE-eligibility criteria and face an increased risk of myocardial reinfarction within 12 months. Early administration of IPE may play an essential role in mitigating residual CV risk detected by high TGs.

KI fragen

Bookmark

View Full Paper